Gastro-protecting effect of gefarnate on chronic erosive gastritis with dyspeptic symptoms Full Text
Chinese Medical Journal, 08/21/2012
Yi–qi D et al. – Gefarnate demonstrates an effective outcome on the mucosal inflammation in patients with chronic erosive gastritis. Endoscopic and inflammation score should be the major indexes used in gastritis–related trials.Methods
- Totally 253 dyspepsia patients confirmed with erosive gastritis were enrolled from six centers in China.
- They randomly received either daily 300 mg gefarnate or 3 g sucralfate for six weeks.
- The primary endpoint was the effective rate of both treatments on endoscopic erosion at week six.
- Gefarnate showed an effective rate of 72% and 67% on endoscopic score and dyspeptic symptom release, which is statistically higher than sucralfate (40.1% and 39.3%, P <0.001, intension–to–treat).
- For histological improvement, gefarnate showed both effective in decreasing mucosal chronic inflammation (57.7% vs. 24.8%, P <0.001, intension–to–treat) and active inflammation (36.4% vs. 23.1%, P <0.05, intension–to–treat) than the control.
- A significant increase of prostaglandins and decrease of myeloperoxidase in mucosa were observed in gefarnate group.
- Severity of erosion is non–relevant to symptoms but Helicobacter pylori (H. pylori) status does affect the outcome of therapy.